Media stories about Seres Therapeutics (NASDAQ:MCRB) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Seres Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 48.9756790520232 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Seres Therapeutics (MCRB) traded down $0.51 during mid-day trading on Friday, hitting $9.46. 159,894 shares of the stock traded hands, compared to its average volume of 111,274. Seres Therapeutics has a twelve month low of $8.85 and a twelve month high of $17.42. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. The stock has a market cap of $383.41, a price-to-earnings ratio of -4.46 and a beta of 0.24.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. The company had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. Seres Therapeutics’s quarterly revenue was up 76.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.46) EPS. research analysts expect that Seres Therapeutics will post -2.33 EPS for the current year.
MCRB has been the topic of several research reports. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Oppenheimer initiated coverage on Seres Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $19.00 target price on the stock. CIBC initiated coverage on shares of Seres Therapeutics in a report on Friday, October 13th. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, Citigroup initiated coverage on shares of Seres Therapeutics in a report on Thursday, October 12th. They issued a “positive” rating and a $19.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $18.00.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/04/seres-therapeutics-mcrb-getting-somewhat-favorable-media-coverage-analysis-finds.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.